The quantitative objective is to identify the effect of testosterone replacement therapy on erythropoiesis in middle aged and aged men due to potential complications that could result.
Background
Throughout history, men have been concerned with strategies to preserve and enhance their virility.
Many creative approaches have been utilized. Testes were viewed as being the source of vigor and longevity for men. For Greek and Roman men, consumption of a substance called "satyricon" was a popular treatment. This substance was a combination of goat and wolf testicular extracts. The 19 th and 20 th centuries brought an emergence of treatment derived from organs: thyroid extract and animal testicular extract were thought to be effective in maintaining virility. Technology progressed, and in the 1930s, it became possible to isolate various androgens from animal tissue. At this time, these substances were applied in clinical situations. 2 Testosterone deficiency in men, oftentimes referred to as "Low T", has become a common concern for men globally. Testosterone is a hormone responsible for the secondary characteristics that appear at puberty. It has a potent effect on stimulating libido, sexual desire, and arousal. Testosterone is also an anabolic hormone that enhances metabolic processes in muscles, bones, bone marrow, the immune system, and the brain. 3, 4 A low testosterone level is a universal finding in hypogonadism in older men. Hypogonadism is a common syndrome among aging men over 60 years of age characterized by symptoms of decreased libido, erectile dysfunction, decreased vitality, decreased muscle mass, increased adiposity, In some countries, notably the USA which represents about 90% of the market for testosterone products, treatment is becoming more widely implemented due to increased public awareness of testosterone replacement promoted by such factors as internet information, safer and more convenient products, and easier access through private physicians and clinics rather than statefunded systems in some countries. 5 In the USA, the market for testosterone therapies has increased from $49 million to almost $400 million between 1997 and 2003, with the majority of prescribing being for men 40 years or older. 6 In contrast, European statistics indicate that 1% or less of men with symptoms of testosterone deficiency are treated. 5 The exception is Germany where hypogonadism is better recognized and more accepted. 5 In Russia, the testosterone market demonstrates doubling of spending on all testosterone preparations between 2001 and 2007. 5 An issue of concern in Russia that may contribute to a lack of increased utilization of testosterone replacement deals with a most commonly prescribed form of replacement, methyl testosterone, which is low cost, yet toxic. Heavy direct marketing activities related to testosterone replacement products to consumers in the USA may have increased awareness and interest in the concept of low testosterone and its effects. 9 Identified symptoms of low testosterone are highlighted in marketing campaigns noted on television as well as in the print media, thereby triggering consumers to self-diagnose and to request testing from healthcare providers. Clinics specializing solely in low testosterone have appeared throughout the world.
In the minds of many consumers, testosterone replacement is viewed as a potential "fountain of youth". Even though advertisements for testosterone replacement products touch on potential adverse effects of this therapy, many consumers fail to comprehend the potential seriousness of potential adverse effects. Their focus is on a treatment perceived by them as simple which on the surface appears to possess the capability to restore vitality and enhance quality of life.
While testosterone deficiency can be diagnosed with sensitive laboratory testing, testosterone replacement should not automatically be instituted without taking a comprehensive medical history and performing a detailed physical examination to rule out other potential causes of testosterone deficiency and to identify any contraindications to therapy. The Endocrine Society published clinical guidelines in 2010 entitled Testosterone Therapy in Adult Men with Androgen Deficiency
Syndromes. 10 These guidelines recommended diagnosing hypogonadism only in men with consistent symptoms and unequivocally low serum testosterone levels. The Society recommended the and increased visceral obesity. 1 Erythrocytosis, the focus of this systematic review, is defined as an increase in the number of circulating red blood cells, especially resulting from a stimulus. This situation of increased red blood cell volume is also known as polycythemia. 15 In terms of red blood cell volume, men with hypogonadism have lower volumes. 1 The anemia in aging hypogonadal men has been suggested to be partly due to the declining testosterone levels and partly due to effects of erythropoietin and erythroid progenitor cells. 1 Testosterone replacement therapy can restore the anemia levels of older men to the normal range. 17, 18 Multiple routes of administration of testosterone replacement products exist: oral, injectable, scrotal and nonscrotal transdermal, buccal testosterone, and testosterone gel. 1 Testosterone can act directly on bone marrow, increasing the number of burst forming units and erythropoietin-responsive cells which can increase red blood cell volume. It has also been reported that enhanced intestinal iron absorption which can contribute to increased red cell production is an effect of testosterone replacement therapy. 19 An early study in 1968 posited that testosterone induces erythropoietin production. 19 This has since been refuted as the assay used in the referenced study is now considered inaccurate because it is indirect and depends on red blood cell turnover. A recent randomized controlled trial of 96 subjects to study the effect of testosterone on erythropoietin production concluded that the hematopoietic effect of testosterone does not appear to be mediated by stimulation of erythropoietin production. 19 Regardless of the mechanism by which there is an association of red blood cell volume increase in patients receiving
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. testosterone replacement, potential consequences of increased volume must be taken into account for patient safety.
Although an increase in red blood cell volume as measured by hemoglobin, hematocrit, and/or red blood cell count is generally beneficial for hypogonadal men with anemia, an increase of blood volume as measured by these parameters can lead to increased blood viscosity and an array of associated problems. This increased viscosity can exacerbate vascular disease. While all potential adverse effects of testosterone replacement therapy are of concern, those associated with increased blood volume pose significant potential risks such as stroke, myocardial infarction, deep vein thrombosis and pulmonary embolism. 1 As a result, the importance of appropriate clinical monitoring of adverse effects is essential to assure patient safety.
The performance of this proposed systematic review will focus on men age 45 and older receiving testosterone replacement therapy and its effect on red blood cell production and volume increase. No other systematic reviews on this topic have been discovered during the review of literature. This information will be important for healthcare providers who prescribe testosterone replacement therapy or manage individuals receiving this intervention. A review of studies will assess the potential significance and prevalence of increased blood volume in men aged 45 and over as measured by hemoglobin, hematocrit, and/or red blood cell count.
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Inclusion criteria

Types of participants
This review will consider studies that include middle aged and aged men (aged 45 or older) with diagnosed testosterone deficiency or men who have been diagnosed with hypogonadism who are receiving testosterone replacement therapy. Participants will not be included if they have prostate cancer or breast cancer.
Types of interventions
This review will consider studies that evaluate red blood cell volume by measuring hematocrit and/or hemoglobin and/or red blood cell count in men aged 45 years or older receiving any type, dose, or scheduled frequency of testosterone replacement therapy compared to men not receiving testosterone replacement therapy.
Types of outcomes
This review will consider studies that include the following outcome measures: hematocrit and/or hemoglobin and/or red blood cell count in middle aged and aged men who have received testosterone replacement therapy due to a diagnosis of hypogonadism/testosterone deficiency. To be considered for inclusion, the studies must also provide that the participants were assessed by measurement of red blood cell volume utilizing the identified measurements to determine if erythropoiesis with resulting erythrocytosis created a state of secondary polycythemia. .
Types of studies
This review will consider both experimental and epidemiological study designs including randomized controlled trials, non-randomized controlled trials, quasi-experimental, before and after studies, placebo controlled trials, prospective and retrospective cohort studies, large clinical experiences, case control studies and analytical cross sectional studies for inclusion.
Search strategy
The search strategy aims to find both published and unpublished studies. A three-step search strategy will be utilized in this review. An initial limited search of MEDLINE and CINAHL will be undertaken followed by analysis of the text words contained in the title and abstract, and of the index terms used to describe article. A second search using all identified keywords and index terms will then be undertaken across all included databases. Thirdly, the reference list of all identified reports and articles will be searched for additional studies. 
Assessment of methodological quality
Papers selected for retrieval will be assessed by two independent reviewers for methodological validity prior to inclusion in the review using standardized critical appraisal instruments from the Joanna Briggs Institute Meta Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI) (Appendix I). Any disagreements that arise between the reviewers will be resolved through discussion, or with a third reviewer.
Data collection
Data will be extracted from papers included in the review using the standardized data extraction tool from JBI-MAStARI (Appendix II). The data extracted will include specific details about the interventions, populations, study methods and outcomes of significance to the review question and specific objectives. The authors will extract data from individual studies independently.
Authors of primary studies will be contacted for missing information or to clarify unclear data.
Data synthesis
Quantitative data will, where possible be pooled in statistical meta-analysis using JBI-MAStARI. All results will be subject to double data entry. Effect sizes expressed as odds ratio (for categorical data) and weighted mean differences (for continuous data) and their 95% confidence intervals will be calculated for analysis. Heterogeneity will be assessed statistically using the standard Chi-square.
Where statistical pooling is not possible the findings will be presented in narrative form including tables and figures to aid in data presentation where appropriate.
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